Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels in the Diagnosis of BMT-associated Hepatic Veno-occlusive Disease and Monitoring of Subsequent Therapy with Defibrotide (DF)
Authors:
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 8 (2) , 91-95
Abstract
Hepatic veno-occlusive disease (VOD) is a common and potentially fatal complication of high dose chemotherapy with allogeneic/autologous stem cell transplant (SCT). The diagnosis and treatment of hepatic VOD is controversial. Clinical features are non-specific and may be mimicked by a number of other conditions causing hyperbilirubinaemia post-transplantation. Plasminogen activator inhibitor-1 (PAI-1) has been proposed as a specific marker of VOD [1]. Defibrotide (DF) is a polydeoxyribonucleotide, which has been found to have anti-thrombotic, anti-ischaemic and thrombolytic properties without causing significant anti-coagulation. Recent evidence [2,3] suggests that use of DF in patients with severe VOD results in a promising response rate without attributable significant toxicity. Between January 1998 and July 1999, PAI-1 levels were measured serially in 16 patients undergoing SCT who had subsequently developed hyperbilirubinaemia. Diagnosis of VOD was made by established clinical criteria [4,5]. At the time of diagnosis, PAI-1 levels (mean±SD) were significantly elevated in patients with VOD (90.7±47 ng/ml, n=7) when compared with patients with jaundice from other causes post transplantation (12.1±6.4 ng/ml, n=9). Five of the patients with VOD received treatment with DF. Four out of five patients showed an initial response to DF (significant fall in bilirubin and improvement in other signs/symptoms) with one of these patients having a complete response (bilirubin < 2.0 mg/dl and full resolution of signs/symptoms and end-organ toxicity). Following treatment with DF, a corresponding fall in PAI-1 levels was noted in those responding, with non-responders maintaining raised levels. Conclusion: Raised PAI-1 levels post stem cell transplant are specific for VOD and a subsequent decrease in levels following treatment with DF may be associated with response to treatment.Keywords
This publication has 7 references indexed in Scilit:
- Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyBritish Journal of Haematology, 2000
- Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.Journal of Clinical Oncology, 1993
- Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liverBlood, 1993
- Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 1993
- DefibrotideDrugs, 1993
- Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markersThrombosis Research, 1991
- VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATIONTransplantation, 1987